Identification of Prognostic RBPs in Osteosarcoma.

Area of Science:

• Oncology
• Molecular Biology
• Bioinformatics

Background:

• Osteosarcoma is a prevalent bone cancer in children and adolescents with a poor prognosis.
• RNA-binding proteins (RBPs) are increasingly recognized for their roles in various malignancies.
• Identifying specific RBPs in osteosarcoma is critical for developing novel therapeutic strategies.

Purpose of the Study:

• To identify key RNA-binding proteins (RBPs) that serve as prognostic factors and potential therapeutic targets in osteosarcoma.
• To explore the biological functions and pathways associated with differentially expressed RBPs in osteosarcoma.
• To validate the prognostic value of identified RBPs and develop a predictive risk model.

Main Methods:

• Downloaded and analyzed the GSE33382 dataset from the Gene Expression Omnibus (GEO) database.
• Performed differential expression analysis, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses.
• Constructed a Protein-protein interaction (PPI) network and utilized Cox regression analysis with TARGET database clinical information for RBP identification and risk model validation.

Main Results:

• Identified 38 differentially expressed RBPs, significantly enriched in ribosome biogenesis and mRNA surveillance pathways.
• DDX24, DDX21, WARS, and IGF2BP2 were identified as significant prognostic factors for osteosarcoma.
• A validated risk score model was generated, and WARS was implicated in osteosarcoma immune infiltration.

Conclusions:

• DDX24, DDX21, WARS, and IGF2BP2 are key players in osteosarcoma development and progression.
• These identified RBPs represent promising therapeutic targets for osteosarcoma treatment.
• Further investigation into the role of these RBPs may lead to improved patient outcomes.